BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bettoni S, Galbusera M, Gastoldi S, Donadelli R, Tentori C, Spartà G, Bresin E, Mele C, Alberti M, Tortajada A, Yebenes H, Remuzzi G, Noris M. Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. J Immunol 2017;199:1021-40. [PMID: 28652401 DOI: 10.4049/jimmunol.1601121] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Agostinis C, Mangogna A, Balduit A, Aghamajidi A, Ricci G, Kishore U, Bulla R. COVID-19, Pre-Eclampsia, and Complement System. Front Immunol 2021;12:775168. [PMID: 34868042 DOI: 10.3389/fimmu.2021.775168] [Reference Citation Analysis]
2 Nolasco JG, Nolasco LH, Da Q, Cirlos S, Ruggeri ZM, Moake JL, Cruz MA. Complement Component C3 Binds to the A3 Domain of von Willebrand Factor. TH Open 2018;2:e338-45. [PMID: 31080944 DOI: 10.1055/s-0038-1672189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Noris M, Daina E, Remuzzi G. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Nephrol Dial Transplant 2021:gfab281. [PMID: 34596686 DOI: 10.1093/ndt/gfab281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Noris M. The case of complement inhibitors. Adv Biol Regul 2021;81:100822. [PMID: 34454870 DOI: 10.1016/j.jbior.2021.100822] [Reference Citation Analysis]
5 Qian D, Liu H, Wang X, Ge J, Luo S, Patz EF Jr, Moorman PG, Su L, Shen S, Christiani DC, Wei Q. Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer 2019;144:1867-76. [PMID: 30259978 DOI: 10.1002/ijc.31896] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
6 Oncul S, Afshar-Kharghan V. The interaction between the complement system and hemostatic factors. Curr Opin Hematol 2020;27:341-52. [PMID: 32701617 DOI: 10.1097/MOH.0000000000000605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
7 Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 2020;98:314-322. [PMID: 32461141 DOI: 10.1016/j.kint.2020.05.013] [Cited by in Crossref: 116] [Cited by in F6Publishing: 110] [Article Influence: 58.0] [Reference Citation Analysis]
8 Upreti H, Kasmani J, Dane K, Braunstein EM, Streiff MB, Shanbhag S, Moliterno AR, Sperati CJ, Gottesman RF, Brodsky RA, Kickler TS, Chaturvedi S. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood 2019;134:1037-45. [PMID: 31431443 DOI: 10.1182/blood.2019001056] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
9 Ruggenenti P, Di Marco F, Cortinovis M, Lorini L, Sala S, Novelli L, Raimondi F, Gastoldi S, Galbusera M, Donadelli R, Mele C, Piras R, Noris M, Portalupi V, Cappelletti L, Carrara C, Tomatis F, Bernardi S, Perna A, Peracchi T, Diadei O, Benigni A, Remuzzi G. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS One 2021;16:e0261113. [PMID: 34928990 DOI: 10.1371/journal.pone.0261113] [Reference Citation Analysis]
10 Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol 2021. [PMID: 34912108 DOI: 10.1038/s41577-021-00665-1] [Reference Citation Analysis]
11 Conway EM. Complement-coagulation connections. Blood Coagul Fibrinolysis 2018;29:243-51. [PMID: 29517503 DOI: 10.1097/MBC.0000000000000720] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 5.8] [Reference Citation Analysis]
12 Perico L, Morigi M, Galbusera M, Pezzotta A, Gastoldi S, Imberti B, Perna A, Ruggenenti P, Donadelli R, Benigni A, Remuzzi G. SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation. Front Immunol 2022;13:827146. [DOI: 10.3389/fimmu.2022.827146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Java A, Apicelli AJ, Liszewski MK, Coler-Reilly A, Atkinson JP, Kim AH, Kulkarni HS. The complement system in COVID-19: friend and foe? JCI Insight 2020;5:140711. [PMID: 32554923 DOI: 10.1172/jci.insight.140711] [Cited by in Crossref: 100] [Cited by in F6Publishing: 87] [Article Influence: 50.0] [Reference Citation Analysis]
14 Dixon BP, Gruppo RA. Atypical Hemolytic Uremic Syndrome. Pediatric Clinics of North America 2018;65:509-25. [DOI: 10.1016/j.pcl.2018.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
15 Kremer Hovinga JA, Heeb SR, Skowronska M, Schaller M. Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. J Thromb Haemost 2018;16:618-29. [DOI: 10.1111/jth.13956] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
16 Bitzan M, Hammad RM, Bonnefoy A, Al Dhaheri WS, Vézina C, Rivard GÉ. Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade. Pediatr Nephrol 2018;33:1437-42. [PMID: 29728803 DOI: 10.1007/s00467-018-3957-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Buelli S, Zoja C, Remuzzi G, Morigi M. Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. Microorganisms 2019;7:E15. [PMID: 30634669 DOI: 10.3390/microorganisms7010015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
18 Budnik I, Brill A. Immune Factors in Deep Vein Thrombosis Initiation. Trends Immunol 2018;39:610-23. [PMID: 29776849 DOI: 10.1016/j.it.2018.04.010] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 14.8] [Reference Citation Analysis]
19 Aradottir SS, Kristoffersson AC, Roumenina LT, Bjerre A, Kashioulis P, Palsson R, Karpman D. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis. Front Immunol 2021;12:690821. [PMID: 34177949 DOI: 10.3389/fimmu.2021.690821] [Reference Citation Analysis]
20 Tan Y, Zhao MH. Complement in glomerular diseases. Nephrology (Carlton) 2018;23 Suppl 4:11-5. [PMID: 30298653 DOI: 10.1111/nep.13461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
21 De Cristofaro R, Liuzzo G, Sacco M, Lancellotti S, Pedicino D, Andreotti F. Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study. Blood Coagul Fibrinolysis 2021;32:285-9. [PMID: 33443926 DOI: 10.1097/MBC.0000000000000998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
22 Vitiello A, La Porta R, D'Aiuto V, Ferrara F. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol 2021;82:264-9. [PMID: 33632561 DOI: 10.1016/j.humimm.2021.01.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
23 Donadelli R, Pulieri P, Piras R, Iatropoulos P, Valoti E, Benigni A, Remuzzi G, Noris M. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. Front Immunol 2018;9:2329. [PMID: 30487789 DOI: 10.3389/fimmu.2018.02329] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
24 Singh AK, Malviya R. Coagulation and inflammation in cancer: Limitations and prospects for treatment. Biochim Biophys Acta Rev Cancer 2022;:188727. [PMID: 35378243 DOI: 10.1016/j.bbcan.2022.188727] [Reference Citation Analysis]
25 Vinci R, Pedicino D, Andreotti F, Russo G, D'Aiello A, De Cristofaro R, Crea F, Liuzzo G. From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19. Int J Cardiol 2021;326:243-7. [PMID: 33181158 DOI: 10.1016/j.ijcard.2020.11.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Fujimura Y, Holland LZ. COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm. Int J Hematol 2022. [PMID: 35316498 DOI: 10.1007/s12185-022-03324-w] [Reference Citation Analysis]
27 Sinkovits G, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Mező B, Csuka D, Hurler L, Kajdácsi E, Cervenak L, Kiszel P, Masszi T, Vályi-Nagy I, Prohászka Z. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality. Thromb Haemost 2022. [PMID: 35062036 DOI: 10.1055/s-0041-1740182] [Reference Citation Analysis]
28 Neves PDMM, Souza RA, Torres FM, Reis FA, Pinheiro RB, Dias CB, Yu L, Woronik V, Furukawa LS, Cavalcante LB, de Almeida Araújo S, Wanderley DC, Malheiros DM, Jorge LB. Evidences of histologic thrombotic microangiopathy and the impact in renal outcomes of patients with IgA nephropathy. PLoS One 2020;15:e0233199. [PMID: 33147224 DOI: 10.1371/journal.pone.0233199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Bauer AT, Gorzelanny C, Gebhardt C, Pantel K, Schneider SW. Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities. Cancer Treatment Reviews 2022;102:102322. [DOI: 10.1016/j.ctrv.2021.102322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Carlisi M, Mancuso S, Caimi G, Siragusa S. Thrombotic risk in paroxysmal nocturnal hemoglobinuria-like (PNH-like) phenotype. Clin Hemorheol Microcirc 2021;79:491-503. [PMID: 32116238 DOI: 10.3233/CH-190735] [Reference Citation Analysis]
31 Gallo CG, Fiorino S, Posabella G, Antonacci D, Tropeano A, Pausini E, Pausini C, Guarniero T, Hong W, Giampieri E, Corazza I, Federico L, de Biase D, Zippi M, Zancanaro M. COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us? Cytokine 2021;148:155628. [PMID: 34411989 DOI: 10.1016/j.cyto.2021.155628] [Reference Citation Analysis]
32 Goel A, Ramakrishna B, Zachariah U, Sajith KG, Burad DK, Kodiatte TA, Keshava SN, Balasubramanian KA, Elias E, Eapen CE. What makes non-cirrhotic portal hypertension a common disease in India? Analysis for environmental factors. Indian J Med Res 2019;149:468-78. [PMID: 31411170 DOI: 10.4103/ijmr.IJMR_1405_17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]